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Temporal profiles of miRNA activity during produc-
tive virus infection can provide fundamental insights
into host-virus interactions. Most reported miRNA
targetome analyses in the context of virus infection
have been performed in latently infected cells and
lack reliable models for quantifying the suppression
efficacy at specific miRNA target sites. Here, we
identified highly competent temporal miRNA targe-
tomes during lytic HCMV infection by using AGO-
CLIP-seq together with a bioinformatic method that
quantifies miRNA functionality at a specific target
site, called ACE-scoring. The repression efficiency
at target sites correlates with the magnitude of the
ACE-score, and temporal HCMV-encoded miRNA
targetomes identified by ACE-scoring were signifi-
cantly enriched in functional categories involved in
pathways central for HCMV biology. Furthermore,
comparative analysis between human and viral
miRNA targetomes supports the existence of inti-
mate cooperation and co-targeting between them.
Our holistic survey provides a valuable resource for
understanding host-virus interactions during lytic
HCMV infection.
INTRODUCTION
Since the first report of viral miRNAs in 2004 (Pfeffer et al.,
2004), numerous viral miRNAs have been discovered, mainly
in herpesviruses (Kincaid and Sullivan, 2012). To date, at least
22 miRNAs encoded by human cytomegalovirus (HCMV),
a b-herpesvirus, have been identified from 12 pre-miRNAs
(Stark et al., 2012). Most target search studies of HCMV-en-
coded miRNAs have been performed at the single miRNA-
single target interaction level or by narrow-range screening
methods (Hook et al., 2014a), necessitating a more accurate
genome-wide targetome analysis during HCMV infection.838 Cell Host & Microbe 17, 838–851, June 10, 2015 ª2015 ElsevierAlthough bioinformatic prediction algorithms have played
valuable roles in the discovery of new miRNA targets, current
algorithms have high false positive or negative rates (Thom-
son et al., 2011). Thus, the genome-wide identification of
authentic miRNA-target interactions requires a combination
of sophisticated biochemical approaches and bioinformatics
analysis. To this end, argonaute-crosslinking and immuno-
precipitation followed by high-throughput sequencing (AGO-
CLIP-seq, also known as Ago HITS-CLIP) methods have
been developed to overcome insufficient in silico prediction
of miRNA-target interaction sites (Chi et al., 2009). AGO-
CLIP-seq methods provide significantly higher resolution
data regarding the precise location of binding sites,
avoiding the potential limitations of miRNA-target search
methods based on mRNA expression profiling and prote-
omics techniques.
Several groups have successfully adopted the AGO-CLIP-seq
method to identify targets of Epstein-Barr virus (EBV) miRNAs
and Kaposi’s sarcoma-associated herpesvirus (KSHV) miRNAs
in the latently infected cell lines with g-herpesviruses (Gottwein
et al., 2011; Haecker et al., 2012; Riley et al., 2012; Skalsky
et al., 2012). However, there have been no temporal investiga-
tions for the miRNA targetomes during productive infection of
miRNA-encoding viruses, including HCMV.
In this study, we describe the application of an AGO-CLIP-
seq-based approach to characterize the global miRNA targe-
tome during productive HCMV infection. We also developed a
bioinformatic quantitation method, ACE-scoring (AGO-CLIP-
seq enrichment scoring), to accurately identify miRNA target
sites and calculate the targeting efficacy of miRNA-target
interactions. We collectively discovered and validated the func-
tionality of miRNA-target interactions and their correlation with
calculated ACE-scores. We observed and verified various
target genes in cellular pathways important for HCMV infection
progression. In addition, comparative analysis between human
miRNA and HCMV miRNA targetomes revealed functional rela-
tionships by co-targeting and cooperation. Our quantitative
temporal data on miRNA targetomes provide a key foothold
for the study of HCMV virology, facilitating the detailed analysis
of and further insight into viral pathogenesis and novel drug
discovery.Inc.
RESULTS
Temporal Features of AGO-CLIP-Seq, mRNA-Seq, and
smallRNA-Seq during Lytic HCMV Infection
To analyze the targetome in HCMV-infected cells, we per-
formed AGO-CLIP-seq in triplicate and both mRNA-seq and
smallRNA-seq in duplicate with human foreskin fibroblasts
(HFFs) uninfected or infected with HCMV Townelong and har-
vested at 0 (uninfected), 24, 48, and 72 hr after infection
(Figure 1A). The expression of phase marker genes and cell
viability were confirmed (Figures 1B and S1A, available online).
To exclude bias in targetome identification from differential
AGO IP efficiency of viral miRNAs, we used the pan-AGO-spe-
cificmousemonoclonal antibody 2A8 (Nelson et al., 2007), which
can capture all human AGO proteins (hAGO1–4; Figure S1B).
From purified UV-crosslinked radioactive AGO-RNA complexes
(Figure 1B), CLIPed RNA-30-adaptor species of 40–77 nt were
excised, purified, and ligated to a 50-RNA adaptor and then
subjected to RT-PCR (Figure 1C). The amplicon libraries yielded
a strong peak at the miRNA or highly digested mRNA-derived
band size (136–145 bp) and exhibited several larger RNA-
derived species (145–170 bp), consistent with prior reports on
CLIP-seq-based AGO-interacting targetome analysis (Chi
et al., 2009; Leung et al., 2011; Riley et al., 2012). We also pre-
pared mRNA-seq and smallRNA-seq libraries to assist with the
complicated data processing and as controls for the compara-
tive analysis of mRNA or miRNA expression (Figures S1C and
S1D).
The sequencing data were processed by pipeline designed in
Figure S1E and were sufficient (Table S1A–S1C) and reproduc-
ible (Figures S1F and S1G). The majority of the AGO-CLIP-seq
reads mapped to human and viral miRNA genomic regions,
and 4%–9% mapped to human mRNA genomic regions (Fig-
ure 1D), consistent with previous observations in AGO-CLIP-
seq-based studies (Leung et al., 2011). The specificity of the
AGO-CLIP-seq method was demonstrated by the relative lack
of AGO crosslinking to highly abundant rRNAs (3.66%–7.64%)
and tRNAs (0.52%–0.76%). Together, the quantity and quality
of the AGO-CLIP-seq, mRNA-seq, and smallRNA-seq reads
were adequate for further bioinformatic miRNA targetome
analysis.
Canonical miRNA target sites are mostly located in the
30-UTRs of mRNAs rather than the 50-UTR or CDS regions
(Fabian et al., 2010). Although a significant fraction of the
AGO-CLIP-seq reads mapped to mRNA CDS regions, consis-
tent with prior reports (Boudreau et al., 2014; Chi et al., 2009;
Hafner et al., 2010), reads in the 30-UTR were enriched 2-fold
in AGO-CLIP-seq (approximately 60%) compared to mRNA-
seq (approximately 30%) (Figure 1D). Additionally, AGO-CLIP-
seq reads near the stop codon were more enriched in the
30-UTR than in CDS regions; however, there was no differential
enrichment between AGO-CLIP-seq and mRNA-seq in the
50-UTR, and there were more CDS reads around the start and
stop codons in mRNA-seq than in AGO-CLIP-seq (Figure 1E).
These results suggested that our AGO-CLIP-seq data might
contain a considerable proportion of clusters that were cross-
linked to AGO proteins together with virtual miRNA target sites
in the 30-UTRs of mRNAs. Thus, we focused on the mRNA
30 UTR as the major targeting site of viral miRNAs.Cell HComprehensive Identification of Canonical Human
Targets of HCMV miRNAs Using ACE-Scoring
To analyze the human mRNA targetome of HCMV miRNAs, we
first characterized the peak clusters of AGO-CLIP-seq reads af-
ter Q value correction as an appropriate peak-calling method for
the identification of miRNA target sites (Figures S2A–S2C). The
observation that the expression of the refined 22 viral miRNAs
exponentially increased during infection (Figures S2D and S2E
and Table S1D) suggested that the relative intensities of the
peak clusters at all the viral miRNA target sites during maximum
viral miRNA targeting efficacy should be increased compared to
earlier time points. Because the number of total AGO-CLIP-seq
reads for eachmRNAwas generally greater when themRNAwas
more highly expressed (Figure S2F), an increase in absolute
depth size within a peak cluster at a given time point compared
to a previous time point does not simply reflect targeting inten-
sity, suggesting that the fold change in AGO-CLIP-seq reads
should be compared to the number of mRNA-seq reads in
a peak cluster. We therefore introduced the concept of an
‘‘increased AGO-CLIP-seq’’ constraint as an indicator of miRNA
targeting intensity and reported this value as the ‘‘ACE-score’’
(AGO-CLIP-seq enrichment score) (Figures 2A and S2A).
Notably, the ACE-scores of the peak clusters that are actively
targeted by viral miRNAs should be positive (ACE-score > 0).
Nonetheless, many positive ACE-score peak cluster regions
might not be viral miRNA target sites because many human
miRNA target sites that show increased expression after infec-
tion might have a positive ACE-score. Although some functional
non-seed target rules have been reported, we observed that
seed-independent target sites were identified at a relatively
lower abundance than seed-dependent sites (Table S2A). More-
over, the representation rate of mutation sites in most viral miR-
NAs in AGO-CLIP-seq reads was enriched in the binding regions
of non-seed nucleotides (Figures S2D, S2G, and S2H), indicating
that most viral miRNAs might exhibit seed site-mediated target
interactions that increase the frequency of UV-crosslinking
during the CLIP-seq procedure for miRNA nucleotides, which
are not base-paired in AGO-miRNA-mRNA ternary complexes.
Therefore, to identify reliable peak clusters targeted by viral
miRNAs, we selected peak clusters containing viral miRNA
seed binding motifs (6-mer, 7-mer-m8, 7-mer-A1, and 8-mer)
(Grimson et al., 2007) with positive ACE-scores. As a result, we
collectively identified 3,909 human targets of the viral miRNAs
from temporal sets of 2,531 (24 hpi), 2,968 (48 hpi), and 1,394
(72 hpi) genes. We defined the target gene groups containing
the seed motif-filtered peak clusters with positive ACE-scores
in the 30 UTR of humanmRNA as the canonical human targetome
of viral miRNAs (HTV) (Figure 2B and Table S3).
ACE-Score Reflects the Targeting Functionality in HTV
To assess the functionality of the HTV targets, the overall fold
changes in mRNA expression of the 3,909 identified HTV targets
were comparedwith the expression fold changes of total mRNAs
and/or non-targets. HTV targets were generally suppressed at
the mRNA level at 24, 48, and 72 hpi compared to the uninfected
control (Figure 2C), and the targeting effects were prolonged
during infection (Figure 2D). HTV targets with an ACE-score >
1 were slightly more suppressed than total HTV targets (ACE-
score > 0) (Figures 2C and 2D). All the HTV targets of individualost & Microbe 17, 838–851, June 10, 2015 ª2015 Elsevier Inc. 839
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Figure 1. Temporal AGO-CLIP-Seq Analysis in HCMV-Infected Cells
(A) Workflow of AGO-CLIP-seq, mRNA-seq, and smallRNA-seq in the context of HCMV infection.
(B) Representative autoradiography and immunoblots of AGO-CLIPed 32P-labeled RNA-AGO complexes from uninfected or infected HFFs after infection for the
indicated times. With aliquots of time point lysates used in AGO-CLIP-seq, immunoblotting was performed with anti-pan-AGO, anti-IE1/2, anti-UL55, anti-UL44,
anti-UL84, anti-UL99, anti-UL83, and anti-GAPDH (loading control) antibodies. The expression phases of viral genes are indicated as IE (immediate early), E
(early), and L (late).
(C) Top: autoradiograph of the RNA urea-polyacrylamide gel after proteinase K treatment and RNA extraction from the indicated Ago-RNA complex region of the
membrane in (B). Bottom: verification of RT-PCR products of 50- and 30-adaptor-ligated CLIPed RNAs after proteinase K treatment and RNA extraction from the
transferred membrane.
(D) Relative fraction of reads mapped to indicated human or HCMV genomic regions of AGO-CLIP-seq, mRNA-seq, and smallRNA-seq data. snRNA, small
nuclear RNA; snoRNA, small nucleolar RNA; mt tRNA, mitochondrial tRNA; miscRNA, miscellaneous RNA; lincRNA, long intergenic non-coding RNA; CDS,
coding sequence; UTR, untranslated region. Relative fraction of reads mapped to human or HCMV miRNA-encoding regions of smallRNA-seq and AGO-CLIP-
seq data and reads mapped to the indicated regions within human mRNAs of AGO-CLIP-seq data are represented.
(E) Relative fraction of AGO-CLIP-seq and mRNA-seq reads mapped to positions (up to ±500 nt) relative to mRNA start and stop codons. Data are plotted as the
normalized density relative to transcript abundance for AGO-CLIP-seq reads (red) or mRNA-seq reads (blue). For each time point, the average value of AGO-
CLIP-seq triplicate or mRNA-seq duplicate read counts was calculated at each position. The AGO-CLIP-seq read count average was divided bymRNA-seq read
count average. Data are presented as the sum of calculated average counts at all times. The mRNAs for this analysis were calculated with length limits > 500 nt in
the 50 UTR, > 1,000 nt in CDS, and > 500 nt in the 30 UTR.
See also Figure S1 and Table S1.viral miRNAs were highly suppressed (Figures S2I and S2J), indi-
cating that all the viral miRNAs were functional during infection.
In determining whether the suppression level corresponded
with the ACE-score, we observed that the first quartile of the840 Cell Host & Microbe 17, 838–851, June 10, 2015 ª2015 ElsevierHTV showed the greatest level of transcriptome suppression,
and the degree of suppression sequentially weakened toward
the last quartile (Figure 2E). The first quartile of the HTV had
the lowest Context+ score (C+ score); this score was developedInc.
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Figure 2. HTV Identification by ACE-Scoring and Targeting Efficacy Evaluation of Temporal HTVs
(A) Scheme of the methodology for peak calling and ACE-score calculation.
(B) Identification and filtering steps for temporal HTVs.
(C) Cumulative fractions for mRNA expression fold change of total HTVs. *p < 0.001, two-sample Kolmogorov-Smirnov test (2-sided).
(D) Median (left) and mean (right) fold changes of data displayed in (C).
(E) Median (upper) and mean (lower) mRNA fold changes of quartiles of temporal HTVs.
(F) Median (upper) and mean (lower) C+ scores of quartiles of temporal HTVs.
See also Figure S2 and Tables S2 and S3.
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to calculate the targeting efficiency using multiple features and
is considered one of the most powerful algorithms to evaluate
miRNA or siRNA targeting efficiency (Garcia et al., 2011). The
C+ score sequentially decreased toward the last quartile (Fig-
ure 2F). Thus, these results indicated that the target suppression
efficacy at the HTV target sites correlated with the magnitude of
the ACE-score.
Unbiased sequence motif enrichment analysis is a useful
method for analyzing the HTV peak cluster regions to evaluate
the likelihood of viral miRNA targeting (Boudreau et al., 2014;
Leung et al., 2011; Zhang and Darnell, 2011). Among MEME
(multiple EM for motif elicitation) (Bailey and Elkan, 1994) motifs
significantly enriched for peak clusters with an ACE-score > 1,
we found that 7 of 10 at 24 hpi, 6 of 10 at 48 hpi, and 6 of 10 at
72 hpi corresponded to viral miRNA seed sequences (Table
S2B, upper tables). Mutations frequently induced in UV-cross-
linked nucleotides during AGO-CLIP-seq have been regarded
as important identifiers of reasonable miRNA target sites (Zhang
and Darnell, 2011). Crosslinking-induced mutation site (CIMS)
analysis of peak clusters can identify the precise interaction
sites, and the significance of the sites can be represented by
the FDR (false discovery rate). We selected peak sites with a
CIMS FDR < 0.05 and performed a MEME analysis of these
peak sites. No obvious enrichment of viral and human miRNA
target sites was observed (Table S2B, lower tables). This result
suggests that although CIMS analysis can be a useful method
for evaluating the accuracy of RNA-binding protein interaction
sites, it is not adequate for identifying all precise miRNA target
sites from genome-wide AGO-CLIP-seq data. Taken together,
we concluded that our temporal HTVs sorted by the ACE-scoring
method represent virtual target genes of viral miRNAs.
Validation of the Suppression of High-Confidence HTV
Targets
To test whether HTV targets were suppressed by the corre-
sponding viral miRNAs, we selected high-confidence candidates
from temporal HTVs (Figure S3A and Table S4) and examined the
fold reduction in mRNA expression by transfecting the targeting
viral miRNAs into HFFs. At 48 hr post-transfection, total RNAwas
extracted and examined by quantitative real-time PCR (qRT-
PCR), which revealed that 26 of 30 mRNAs were significantly
downregulated (Figure 3A).
To further investigate whether high-confidence HTV target in-
teractions weremediated by seed binding, we constructed firefly
luciferase reporters for either wild-type target 30 UTR (WT) or
seed-mutated target 30 UTR (Mut) (Figure S3B). Dual luciferase
assays were performed, and 26 of 30 miRNA-target mRNA com-
binations showed decreased luciferase activity in theWT context
compared to control miRNA, but the relative luciferase activities
of theMut were comparable with or recovered toward the control
miRNA transfections (Figure 3B). These results validated the
reliability of high-confidence HTV targets and provided a basis
for further functional investigations of our ACE-score-supported
HTV targets.
Functional Significance for Sub-temporal HTVs over the
Course of Productive Infection
To ascertain more detailed information on the temporal HTVs,
we divided the three temporal HTV groups (24 hpi HTV,842 Cell Host & Microbe 17, 838–851, June 10, 2015 ª2015 Elsevier48 hpi HTV, and 72 hpi HTV) into seven sub-temporal groups
(HTV-E, HTV-EM, HTV-M, HTV-ML, HTV-L, HTV-EL, and
HTV-All; E, early; M, mid; L, late) based on overlap among
the temporal groups (Figure 4A). The time course comparison
analysis of the fold change in the sub-temporal HTVs at the
transcriptome level revealed that the repression of earlier
sub-temporal HTVs was greatest in the early phase, whereas
that of later sub-temporal HTVs was maximal in the late phase
(Figure 4B). These results indicated that sub-temporal HTVs
might undergo time-dependent target suppression with
maximal target suppression efficacy during their representative
time points. Because all HCMV miRNAs are increasingly ex-
pressed during productive infection (Figure S2E), the target
suppression of viral miRNAs might theoretically continue and
gradually accumulate during infection. When mRNAs that are
transcriptionally induced by infection stimuli are targeted by
viral miRNAs, a positive ACE-score can occur at a later phase
of infection due to sustained target suppression by increasingly
expressed viral miRNAs and on the characteristics of ACE-
score calculation. Thus, all sub-temporal HTVs are continually
suppressed by viral miRNAs during infection, and maximum
target suppression periods might be determined by the induc-
ibility of target transcripts after infection.
To further investigate which factors affect the relatively high
propensity toward the upregulation of late time-specific tempo-
ral targetomes at the early phase of infection, we hypothesized
that genes induced and activated by viral entry and viral gene
function at the immediate-early stage might be upstream regula-
tors of the initial induction of late time-specific HTV targets.
Therefore, we performed an upstream analysis using ingenuity
pathway analysis of 72 hpi HTV genes upregulated at 24 hpi
compared to the uninfected state and determined that several
genes (MAPK8, PDGFB, MAPK1, HIF1A, JUN, CEBPB, EGFR,
TNF, CCL5, RUVBL1, ERG, DNMT3B, EGF, and MYC) that are
known to be activated or induced at the initial stage of HCMV
infection were significantly enriched (Figure 4C and Table S5)
(Boldogh et al., 1991; Kapoor et al., 2012; McFarlane et al.,
2011; Rodems and Spector, 1998; Soroceanu et al., 2008;
Wang et al., 2003; Xuan et al., 2009). These results suggested
that HCMV miRNAs can regulate the expression of downstream
genes, which might be represented in later-phase HTV targets
and induced by viral entry stimuli or viral IE gene expression
through the early-to-late stages of productive infection in a buff-
ering-like manner.
To determine the functional features of sub-temporal HTVs
and all the HTV targets, we performed gene ontology (GO)
analysis and network clustering of GO terms using ClueGO,
a Cytoscape plug-in software (Bindea et al., 2009), and visual-
ized particularly enriched functional annotation categories as a
network (Figures 4D and S4 and Table S6). In agreement with
thewidespread roles of HTV targets, these enriched terms repre-
sent several important aspects of HCMV infection, such as cell-
cycle regulation, which is associated with pseudo G1 phase
establishment in HCMV infection (Sanchez and Spector, 2008),
apoptosis inhibition, which is typically harmful to virus produc-
tion, autophagy regulation, which is utilized by many viruses to
produce viral particles and inhibit anti-viral autophagy mecha-
nisms (Yordy et al., 2013), and secretory pathway consistent
with a recent study (Hook et al., 2014b). Therefore, it indicatedInc.
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Figure 3. Validation of High-Confidence HTV Targets
(A) Fold changes of mRNAs targeted by corresponding HCMV miRNAs. The expression levels of target mRNAs were analyzed using qRT-PCR. *p < 0.05,
**p < 0.01, ***p < 0.001, bootstrapped t test with 10,000 repetitions, compared with control miRNA. Data are presented relative to the value of b-actin as
means ± SEM, n = 3.
(B) Relative luminescence of firefly luciferase withwild-type (WT) or seed-mutated (Mut) target 30 UTRswith corresponding HCMVmiRNAs. Dual luciferase assays
were performed in HEK293T cells using 20 pmol of miRNA oligomer duplexes, 5 ng of the pDEST-GL3-30 UTR vector, and 2.5 ng of the Renilla control vector in a
24-well format. *p < 0.05, **p < 0.01, ***p < 0.001, bootstrapped t test with 10,000 repetitions, compared with control miRNA. Data are presented by dual
normalization (Target[Firefly/Renilla] divided by Mock[Firefly/Renilla]) of the luminescence of firefly luciferase ‘‘relative’’ to the luminescence of Renilla luciferase
as means ± SEM, n = 3.
See also Figure S3 and Table S4.that GO analysis for temporal HTVs can provide the functional
landscape for HCMV miRNAs.
HTV Targets Associated with Cell Cycle, Apoptosis, and
Autophagy
To assess whether genes involved in the biological pathways
important for HCMV are functionally relevant, we analyzed
several HTV targets that are associated with cell cycle,
apoptosis, and autophagy. In cell-cycle regulation, we focused
on CCND1 and CDK6 as HTV targets (Figure S5A and Table
S3), which has been studied more intensively than that of other
cell-cycle checkpoint genes in HCMV infection and associated
with pseudo-G1 phase establishment in HCMV-infected cellsCell H(Sanchez and Spector, 2008). We also identified FAS, FADD,
CASP2, CASP3, and CASP7, which are related to the apoptosis
signaling pathway (Figure S5B and Table S3), and ULK1, ULK2,
ATG2B, ATG5, ATG9A, ATG12, ATG13, ATG16L1, GABARAP,
GABARAPL2, andMAP1LC3B, which are associated with auto-
phagy inhibition (Figure S5C and Table S3). We found that the
mRNA levels of these HTV target genes were reduced upon
transfection of corresponding viral miRNA mimics in HFFs (Fig-
ures 5A and S5D) and further verified by luciferase reporter as-
says for the 30 UTRs of target mRNAs (Figure 5B), validating
that these HTV targets are authentic targets of HCMV miRNAs.
We also observed the protein downregulation of some of these
genes tested (Figure 5C).ost & Microbe 17, 838–851, June 10, 2015 ª2015 Elsevier Inc. 843
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Figure 4. Emergent Property and Functional Landscape of Sub-temporal HTVs
(A) Venn diagram of seven sub-temporal HTVs. Sub-temporal HTV names are indicated as bold characters. Graphical symbols and the number of target genes
(ACE-score > 0) for sub-temporal HTVs are shown below the names. Red dots in three circles indicate the representing periods of sub-temporal HTVs.
(B) Median and mean fold changes of sub-temporal HTVs at the transcriptome level. Upper panels: fold changes compared to previous time point. Lower panels:
fold changes compared to uninfected time point.
(C) Upstream analysis for 72 hpi HTV targets. 72 hpi HTV genes were subjected to upstream analysis using IPA (www.ingenuity.com). Several 72 hpi HTV genes
were clustered by central nodes of 14main activator genes, which are indicated by enlarged purple characters. Arrows represent activation or induction direction
to downstream target genes.
(D) Summary of representative GO categories. GO analysis and functional clustering were performed using ClueGO plugin in Cytoscape program. Blue boxes
indicate significantly enriched representation of GO categories in those sub-temporal HTVs.
See also Figure S4 and Tables S5 and S6.We observed that HFFs transfected with HCMV miRNAs
exhibited a suppressive effect on cell-cycle progression, such
as inducing G1 arrest (Figures 5D and S5E), further strength-
ening the physiological significances. Moreover, we found
that a mixture of HCMV miRNAs downregulated FAS-mediated
apoptosis compared to non-targeting control miRNAs using a
lactate dehydrogenase (LDH) release assay (Figure 5E). In re-
gards to viral miRNA-mediated regulation of the autophagosome
formation, the number of autophagic GFP-LC3 puncta induced
by serum starvation was lower in viral miRNA-transfected cells
than in control miRNA-transfected cells (Figure 5F). Therefore,844 Cell Host & Microbe 17, 838–851, June 10, 2015 ª2015 Elsevierwe concluded that HCMV miRNAs collectively target various
cellular mRNAs to establish the pseudo-G1 phase, regulate
apoptotic signaling ensuring its survival, and inhibit the formation
of autophagosomes.
Modulation of Interferon JAK/STAT Signaling Pathway
through miRNA-Mediated HTV Suppression
Viruses counteract the interferon (IFN) signaling pathway with
viral proteins immediately after infection and throughout the
course of infection. The specific mechanisms used by HCMV
to evade IFN responses have been primarily studied withInc.
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Figure 5. Functional Validation of HTV Targets Related to Cell Cycle and Apoptosis
(A) Relative fold changes of CDK6 and CCND1 mRNAs in HFFs transfected with the corresponding HCMVmiRNAs. The expression levels of target mRNAs were
analyzed using qRT-PCR. *p < 0.05, **p < 0.01, bootstrapped t test with 10,000 repetitions, comparedwith control miRNA. Data are presented relative to the value
of b-actin as means ± SEM, n = 3.
(B) Dual luciferase assay of relative luminescence of firefly luciferase with FAS, FADD, CASP3, CASP7, ATG5, ATG16L2, and GABARAP 30 UTRs with the
corresponding HCMV miRNAs. Dual luciferase assays were performed in HEK293T cells under the same condition as that in Figure 3B. *p < 0.05, **p < 0.01,
bootstrapped t test with 10,000 repetitions, compared with control miRNA. Data are presented by dual normalization of the luminescence of firefly luciferase
relative to the luminescence of Renilla luciferase as means ± SEM, n = 3.
(C) Immunoblots of CCND1, CDK6, FAS, CASP2, CASP3, CASP7, and ATG5 in HFFs transfected with the corresponding HCMV miRNAs. HCMV miRNA
mixes were mixtures of hcmv-miR-UL112-3p, -UL22A-5p, and -US33-5p in CCND1 immunoblots and hcmv-miR-UL36-3p, -US25-1-3p, -US5-1, -US5-2-3p,
and -US25-2-3p in CDK6 immunoblots. Anti-ATG5 antibody was used to detect ATG5-ATG12 conjugates. Alpha-tubulin (a-Tubulin), heat shock protein 70
(HSP70), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as the protein loading control.
(D) Frequency alteration of G1/G0-arrested cells by HCMVmiRNAs. HFF cells were transfected with the synthetic miRNAmimics indicated. After 48 hr, 100 ng/ml
of nocodazole were treated and incubated for 24 hr. PI stained cells were then analyzed by flow cytometry. *p < 0.05, **p < 0.01, ***p < 0.001, bootstrapped t test
with 10,000 repetitions, compared with control miRNA. Data are presented as means ± SEM, n = 3.
(legend continued on next page)
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respect to IE1 protein function mediated by the interaction be-
tween STAT1 and STAT2, which relocalize into PML bodies
(Amsler et al., 2013). Although the disruption of type I and II
IFN signaling can be explained solely by IE1 activity, all of the
mechanisms by which the protein levels of IFNAR1, IFNAR2,
JAK1, STAT1, and STAT2 are reduced during HCMV infection
(Weekes et al., 2014) have not been completely elucidated.
Thus, we aimed to identify the targets in HTV that are associ-
ated with the IFN JAK/STAT pathways. IFNAR1, IFNAR2,
IFNGR2, JAK1, JAK2, STAT1, STAT2, and IL10R2 were pre-
dicted to be HTV targets (Figure 6A and Table S3). We vali-
dated the functionality of the targeting interactions using
luciferase reporter assays (Figure 6B) and qRT-PCR for tran-
scripts (Figure S6A). The reductions in STAT1 and STAT2
protein expression by the corresponding viral miRNAs were
confirmed by immunoblotting (Figure 6C). To access the func-
tionality of viral miRNAs in IFN signaling pathways, we exam-
ined whether IFN-stimulated genes (ISGs) were induced in
HFFs by type I IFN-b or type II IFN-g treatment with or without
viral miRNA transfection. ISG induction was inhibited by viral
miRNA transfection after either IFN-b (Figures 6D and S6B) or
IFN-g treatment (Figures 6E and S6C), except in the case of
miR-UL112-3p.
To validate the physiological relevance under conditions of
HCMV infection, we pre-treated HFFs with either mixed viral
miRNA mimics or anti-microRNA oligonucleotide (AMO) inhibi-
tors. At 6 hr after transfection, the cells were infected with
HCMV for 48 hr, and the induction of ISGs in response to type
I IFN-b or type II IFN-g treatment was determined. The AMO-
mediated inhibition of viral miRNA expression and function had
a de-suppressive effect on IFN-signaling-related targets of
HCMV miRNAs during infection (Figures 6F and S6D), while the
miRNA mimics had an enhancing effect for their signaling sup-
pression (Figures 6G and S6E). Taken together, these results
indicated that HCMV can inhibit IFN JAK/STAT signaling path-
ways by expressingmiRNAs in addition to viral proteins and sug-
gested a mechanism for the regulation of IFN signaling during
HCMV infection.
Co-targeting and Cooperativity between HCMV and
Human miRNA Targetomes
We aimed to identify the targetomes of humanmiRNAs that were
dramatically increased or decreased during HCMV infection.
With 299 human miRNAs expressed at a meaningful level, which
have AGO-CLIP-seq RPM (reads per million reads) values of >50
at least at once in the four time points, we found 39 increased
human miRNAs and 25 decreased human miRNAs (Figure 7A),
of which the fold changes were highly correlated between small-
RNA-seq and AGO-CLIP-seq (Figure 7B). Using our ACE-score-
based method, canonical human 30 UTR targets of upregulated
human miRNAs (HTI, human targetome of increased human(E) Lactate dehydrogenase (LDH) release assay in HeLa cells transfectedwith the i
(sFASL) treatment. Minimum andmaximum releases of LDH from transfected/unt
from experimental cells was calculated and shown in the graph as means ± SEM
(F) Representative images (bar, 5 mm) and the number of GFP-LC3 positive punc
was induced by cultivation of cells in serum-free DMEM for 6 hr or treatment wi
Between 50 and 100 cells were analyzed per assay. ***p < 0.001, Poisson GLM
See also Figure S5.
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getome of decreased human miRNAs) were defined by ACE-
score cut-off of >1 and <1, respectively. We found that the
overall mRNA expression of HTI targets, but not of HTD targets,
gradually decreased after infection (Figure 7C). Also, the expres-
sion of the majority of the individual HTI targets significantly
decreased, whereas the HTD targets were not increased
(Figure 7D).
Here, we hypothesized that the increased target repression
activity of human miRNAs that were upregulated after infection
would be potentiated by co-targeting with HCMV miRNAs,
whereas weakened target de-repression effects of downre-
gulated human miRNAs would be a consequence of target
sharing with HTV targets. To address these issues, we inves-
tigated the target overlap between HTV targets and HTI
targets and found that approximately 86% (2,770/3,202) of
HTV targets (ACE-score > 1) were shared with approximately
58% (2,770/4,772) of HTI targets (ACE-score > 1) (Figure 7E).
Overlapping targets (Overlap) showed the greatest suppres-
sion, whereas non-overlapping HTV and HTI targets (HTV-
only and HTI-only, respectively) exhibited relatively moderate
downregulation (Figure 7F). The relative suppression efficiency
of HTI was slightly greater than that of HTV, indicating that
sharing targets with HTI might intensify the suppression of
most HTV targets.
Next, to elucidate the functional aspects of HCMV miRNA-
specific HTVs (Table S7), we performed GO analysis and
network clustering of enriched terms using ClueGO for 432
HTV-only targets (Figure S7). Terms associated with ‘‘nuclear
division’’ and ‘‘cell cycle’’ as well as ‘‘processing of protein and
RNA’’ are significantly enriched, suggesting that the functionality
of HCMV miRNA-specific targeting itself might be physiologi-
cally relevant in regards to cell-cycle arrest, the regulation of
host gene production, and the enhancement of viral gene pro-
duction and assembly.
We also compared HTV targets with HTD targets and identi-
fied relatively a few (214) HTD targets with an ACE-score < 1
(Figure7G). The fold changesofHTV-only targets (ACE-score>1,
approximately 95%, 3,043/3,202) were similar to those of all HTV
targets (Figure 7H, compared to Figure 2D), whereas HTD-only
targets (ACE-score < 1, approximately 26%, 55/214) were
upregulated due to de-repression as a result of downregulated
human miRNAs. Overlapping targets (159 targets) were only
slightly regulated, suggesting a potential combined effect of
both repression by HTVs and de-repression by HTDs. Thus,
the overall inefficient de-repression activity of HTDs might result
from sharing the majority of HTD targets (approximately 74%,
159/214) with HTVs, indicating that by co-targeting with viral
miRNAs during HCMV infection, target de-repression due to
downregulated miRNAs is less significant than the potentiated
suppression of increased miRNAs.ndicated HCMVmiRNAmixture without or with recombinant soluble FAS ligand
reated HFFs are indicated as percentages (0%–100%). Relative release of LDH
, n = 3.
ta per cell in HeLa cells transfected with control or HCMV miRNAs. Autophagy
th chloroquine at 100 mM for 6 hr as an inducer of autophagosome formation.
tests.
Inc.
IFNAR1
miR-UL36-3p
IFNAR2
Tyk2 Jak1
IFNGR1 IFNGR2
Jak1
Type I IFN
IFNα/β
miR-US29-5p
miR-US5-1
miR-US5-2-3p
miR-UL36-3p
miR-US25-2-3p
Jak2
P
P
P
P
Type II IFN
IFNγ
GAS ISRE
IFNLR1 IL10RB
Tyk2Jak1
miR-UL22A-3p
Type III IFN
 IFN-λ1/
miR-UL112-3p
MX1, ISG15...ICAM1, IRF1 ...
Extracellular
space
Cytosol
Nucleus
A
STAT1
STAT2
STAT1
STAT1
miR-US25-2-3p
miR-US29-3p
miR-US5-2-3p
miR-US5-2-3p
P
P
P
P
IRF9
miR-UL112-3p
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
C
on
tro
l
m
iR
-U
S
4-
3p
m
iR
-U
L3
6-
3p
C
on
t ro
l
m
iR
- U
S
29
-5
p
m
i R
-U
S
5-
1
m
iR
-U
S
5-
2-
3p
C
on
tr o
l
m
iR
- U
L3
6 -
3 p
C
on
tro
l
m
i R
-U
S
29
-3
p
m
iR
- U
S
25
- 2
-3
p
m
iR
-U
S
5-
2-
3 p
C
on
tro
l
m
iR
-U
S
5 -
2-
3p
C
on
tro
l
m
i R
-U
L1
1 2
-3
p
C
o n
tro
l
m
i R
-U
S
25
- 2
- 3
p
IFNAR1 IFNAR2 IFNGR2 STAT1 STAT2 JAK1 JAK2
R
el
at
iv
e 
Lu
m
in
es
ce
nc
e
(T
ar
ge
t[F
/R
]/M
oc
k[
F/
R
])
Co
ntr
ol 
mi
RN
A
mi
R-
US
29
-3p
mi
R-
US
25
-2-
3p
mi
R-
US
5-2
-3p
STAT1
GAPDH
Co
ntr
ol 
mi
RN
A
mi
R-
US
29
-3p
STAT2
GAPDH
C
B
0
100
600
800
1,000
1,200
200
0
100
200
300
400
R
el
at
iv
e 
m
R
N
A
 L
ev
el
(IS
G
15
/β
-a
ct
in
)
C
on
t ro
l
m
i R
N
A
m
ix
C
o n
tr o
l
m
iR
N
A
m
i x
C
on
tro
l
m
iR
N
A
m
i x
C
o n
tr o
l
m
iR
N
A
m
ix
– + – +
C
on
tro
l
m
iR
-U
S5
-1
m
iR
-U
S5
-2
-3
p
m
iR
-U
L3
6-
3p
m
iR
-U
L1
12
-3
p
m
iR
-U
S 2
9-
3p
m
i R
-U
S2
5-
2 -
3p
C
on
tro
l
m
i R
-U
S 5
-1
m
iR
- U
S5
- 2
- 3
p
m
iR
- U
L 3
6-
3p
m
iR
-U
L 1
12
-3
p
m
iR
- U
S 2
9 -
3p
m
iR
-U
S 2
5-
2-
3p
– +
IFN-β
(500 U/ml, 24 hr)
IFN-β
(2,500 U/ml, 24 hr)
R
el
at
iv
e 
m
R
N
A
 L
ev
el
(IC
A
M
1/
β-
ac
tin
)
0
2
4
6
8
10
12
14
0
1
2
3
4
5
6
C
on
tro
l
m
iR
-U
S5
-2
-3
p
m
iR
-U
L3
6-
3p
m
iR
- U
L 1
12
-3
p
m
iR
-U
S2
9-
3p
m
iR
- U
S2
5-
2-
3p
m
iR
-U
S5
- 2
-3
p
m
iR
- U
L 3
6-
3 p
m
iR
-U
L 1
1 2
-3
p
m
iR
-U
S2
9-
3p
m
iR
- U
S2
5-
2-
3p
C
on
tro
l
m
iR
N
A
m
ix
C
on
t ro
l
m
iR
N
A
m
i x
– +
IFN-γ
(50 U/ml, 4 hr)
– +
C
on
tro
l
D E
n.s.
** **
****
** ****
* *
n.s. n.s.
*
* * * * *
*
n.s.
** **
**
n.s.
*
n.s.
100 35.7 73.1 55.2
Relative intensity (%)
100 52.9
Relative intensity (%)
F G
R
el
at
iv
e 
m
R
N
A
 L
ev
el
(IS
G
15
/ β
-a
ct
in
)
R
el
at
iv
e 
m
R
N
A
 L
ev
el
(IC
A
M
1/
β -
ac
tin
)
0
10
20
30
40
50
60
70
80
C
on
tro
l
In
hi
bi
to
rs
– + – +
: IFN-β
: Infection
– +
C
on
tro
l
In
hi
bi
to
rs
C
on
tro
l
In
hi
bi
to
rs
C
on
tro
l
In
hi
bi
to
rs
R
el
at
iv
e 
m
R
N
A
 le
ve
l
(IS
G
15
/G
A
P
D
H
)
0
10
20
30
40
50
60
70
80
– + – +
: IFN-β
: Infection
– +
C
on
tro
l
M
im
ic
s
C
on
tro
l
M
im
ic
s
C
on
tro
l
M
im
ic
s
C
on
tro
l
M
im
ic
s
R
el
at
iv
e 
m
R
N
A
 le
ve
l
(IS
G
15
/G
A
P
D
H
)
0
5
10
15
20
25
30
C
on
tro
l
In
hi
bi
to
rs
– + – +
: IFN-γ
: Infection
– +
C
on
tro
l
In
hi
bi
to
rs
C
on
tro
l
In
hi
bi
to
rs
C
on
tro
l
In
hi
bi
to
rs
R
el
at
iv
e 
m
R
N
A
 le
ve
l
(IC
A
M
1/
G
A
P
D
H
)
0
1
2
3
4
5
6
7
8
– + – +
: IFN-γ
: Infection
– +
C
on
tro
l
M
im
ic
s
C
on
tro
l
M
im
ic
s
C
on
tro
l
M
im
ic
s
C
on
tro
l
M
im
ic
s
R
el
at
iv
e 
m
R
N
A
 le
ve
l
(IC
A
M
1/
G
A
P
D
H
)**
***
***
**
**
Figure 6. Physiological Relevance of HTV Targets Associated with IFN Signaling Pathway
(A) Schematic depiction of interferon (IFN) JAK-STAT pathway with HTV targets.
(B) Dual luciferase assay of relative luminescence of firefly luciferase with IFNAR1, IFNAR2, IFNGR2, STAT1, STAT2, JAK1, and JAK2 30 UTRs with the corre-
sponding HCMV miRNAs. *p < 0.05, **p < 0.01, bootstrapped t test with 10,000 repetitions, compared with control miRNA. Data are presented by dual
normalization of the luminescence of firefly luciferase relative to the luminescence of Renilla luciferase as means ± SEM, n = 3.
(C) Immunoblots of STAT1 and STAT2 proteins in HFFs transfected with the corresponding HCMV miRNAs. GAPDH was served as the protein loading control.
(D and E) Relative levels of ISG15 (D) and ICAM1 (E) mRNA induced by IFN-b (D) or IFN-g (E) treatment of HFFs transfected with control or HCMV miRNAs.
500 U/ml or 2,500 U/ml of IFN-b (PeproTech) were treated for 24 hr, and 50 U/ml of IFN-g (PeproTech) was treated for 4 hr.
(F and G) Relative levels of ISGmRNAs induced by IFN-b or IFN-g treatment of uninfected or HCMV-infected HFFs transfectedwith inhibitors ormimicmixtures of
control or HCMVmiRNAs. Before 6 hr of HCMV infection, control inhibitor or mixed ZENmodified 20-O-methyl AMO inhibitors for HCMVmiRNAs (F), and control
(legend continued on next page)
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DISCUSSION
In this study, we applied genome-wide comparative analysis to
AGO-CLIP-seq data from HCMV-infected cells and uninfected
cells. Our analysis in the context of dynamic infection is a pio-
neering approach for AGO-CLIP-seq-based miRNA targetomics
that is distinct from most previous studies performed in homo-
typic cells or heterogeneous tissue samples without compara-
tive controls. The inclusion of the uninfected control in our
AGO-CLIP-seq analysis improved the accuracy of authentic
target site identification for viral or human miRNAs and enabled
us to elucidate physiologically significant changes during HCMV
infection using our ACE-scoring method.
Several previous studies have already shown that most viral
miRNAs have functions similar to those of viral proteins by
co-targeting common pathways or cellular processes for viral
benefit (Jackson et al., 2011; Kim et al., 2011; Lee et al., 2012;
Stern-Ginossar et al., 2007). In this study, we validated many
genes related to cell cycle, apoptosis, autophagy, and IFN
signaling pathways, which were represented as HTV targets
that have been previously studied in the context of protein-cod-
ing viral gene-mediated regulation. In the pseudo-G1 state, the
steady-state mRNA and protein levels of S-cyclin A and G1-cy-
clin D1 are diminished. Although viral processes are mediated
mainly by pUL69 and pp71 immediately following infection and
subsequently by IE1/IE2 andUL37 IE RNA during the early phase
(Sanchez and Spector, 2008), viral miRNAs can also help prolong
the pseudo-G1 state. To suppress the apoptosis of infected
cells, HCMV encodes multiple apoptosis inhibitors, such as
UL36, UL37, IE1, IE2, UL38, and non-coding RNA b2.7 (McCor-
mick, 2008). FAS downregulation in HCMV-infected cells has
been reported at the late phase of infection with lack of precise
mechanism study (Seirafian et al., 2014). It might be partly ex-
plained by the viral miRNA-mediated mechanism uncovered
previously. HCMV has been also reported to induce autophagy
at the very early phase of infection and to inhibit autophagosome
formation by viral gene expression during the later phase of
infection, which was characterized in part by investigating
HCMV TRS1 protein function (Chaumorcel et al., 2012). Although
distinct domains of TRS1 interact with Beclin and affected by
TRS1 deletion, we additionally showed that autophagy inhibition
at the later phase of HCMV infection can be affected by HCMV-
encoded miRNAs. Thus, our results support the idea that viruses
execute redundant strategies to regulate host cellular processes
by using their protein coding genes and non-coding RNA,
including miRNAs, collectively.
Virus infection can affect host miRNA expression and function
through either direct regulation of viral gene products or the host
anti-viral response. This prompted us to examinewhether dynam-
ically upregulated human miRNAs can cooperate with HCMV
miRNAs by sharing common targets or targeting commonmolec-
ularpathwaysandwhether targetde-repressionofdownregulated
human miRNAs might be diminished by sharing targets with viralmiRNA or HCMV miRNA mimic mixture (G) were transfected in HFF cells for 6 hr
quantified the relative levels of ISG15 and ICAM1 mRNA induced by IFN-b or IFN
(D–G) The expression levels of target mRNAs were analyzed using qRT-PCR. *p
control miRNA. Data are presented relative to the value of b-actin as means ± S
See also Figure S6.
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miRNA targets were shared with viral miRNAs, and the targeting
efficiency of upregulated human miRNAs was more suppressed,
whereas the targetome of downregulated human miRNAs was
not sufficiently de-repressed, indicating that viral miRNAs might
utilize the targeting ability of host miRNAs to regulate their target
selection. However, evolutionary conservation of targetome
sharing between viral and host miRNAs remains to be studied.
Because virally encoded miRNAs are non-immunogenic, un-
like viral proteins that can elicit strong immune responses, it
was not too surprising that HCMV, which is a master of immune
evasion, uniquely developed its miRNAs to escape both host
innate and adaptive immune responses. Most HCMV miRNAs
are expressed and function in latently infected cells (Shen
et al., 2014), indicating that treatments against the expression
and function of viral miRNAs have a potential to affect the estab-
lishment of latent infection. Despite numerous efforts for over 30
years to develop HCMV vaccines that target viral proteins, no
vaccine appears to be approaching imminent licensure (Dasari
et al., 2013; Schleiss, 2008). Thus, our targetome data could
be used to identify novel drug targets and to improve our under-
standing of HCMV virology.
To understand cellular processes in lytic HCMV-infected cells,
comprehensive genome-wide approaches should be used in an
unbiased manner. Recent genome-wide studies of ribosomal
profiling and quantitative proteomics are good examples in the
context of productive HCMV infection (Stern-Ginossar et al.,
2012; Weekes et al., 2014). Therefore, together with these
studies that employed large-scale screening of translated open
reading frames and temporal alteration of viral proteomes, our
study characterizing temporal miRNA targetomes in productive
HCMV-infected cells is an invaluable resource for establishing
a holistic perspective on host-virus interactions.
EXPERIMENTAL PROCEDURES
A full description of Experimental Procedures is available in the Supplemental
Information.
Cell Lines
HFFs, HEK293T cells, and HeLa cells were obtained from the American
Type Culture Collection and cultured in complete DMEM (Hyclone) supple-
mented with 10% FBS (Hyclone), 2 mM GlutaMAX-I (Gibco), 100 U/ml peni-
cillin (Invitrogen), and 100 mg/ml streptomycin (Invitrogen) at 37C in the
presence of 5% CO2. To arrest cell-cycle progression at the pseudo-meta-
phase, 100 ng/ml of nocodazole were treated and incubated for 24 hr.
HCMV Infection
HFF cells were trypsinized, resuspended, and plated at near confluence. All in-
fections were performed with the HCMV Townelong strain (Bradley et al., 2009)
at multiplicity of infection (moi) = 3 and with five immunofluorescence units
(IFU) per cell. DMEM without serum was used for mock infections. After virus
absorption for 1 hr, virus-containing medium was immediately replaced by
complete DMEM. Cells were harvested at the indicated post-infection times
after washing with PBS twice.and then infected without or with HCMV at 1 moi. After 48 hr, by qRT-PCR, we
-g treatment for 16 hr, respectively.
< 0.05, **p < 0.01, bootstrapped t test with 10,000 repetitions, compared with
EM, n = 3.
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Figure 7. Characterization of the Targetomes of Human miRNAs Dynamically Changed during HCMV Infection
(A) Hierarchical cluster heatmap of fold changes (log2) of highly AGO-loaded human miRNAs with >50 RPM (reads per million) in AGO-CLIP-seq data during
HCMV infection. Increased human miRNAs are highlighted and listed in red. Decreased human miRNAs are highlighted and listed in blue.
(B) Correlation between fold changes (log2) of increased or decreased humanmiRNAs indicated in (A) in smallRNA-seq and AGO-CLIP-seq. Data are compared to
RPM values of uninfected samples and averages of duplicate smallRNA-seq and triplicate AGO-CLIP-seq.
(C) Cumulative fractions for mRNA expression fold change of increased human miRNAs (HTI) and decreased human miRNAs (HTD) at specified times.
***p < 0.001, two-sample Kolmogorov-Smirnov test (2-sided).
(D) Fold changes of targets of individual HTIs and HTDs. Left: data are displayed as median fold changes (log2, relative to uninfected RPKM). Right: data from the
left panel are replotted with indicators: whiskers (min/max), boxes (10%–90%), bold bar (mean).
(E) Venn diagram of HTV (ACE-score > 1, red) and HTI (ACE-score > 1, blue). The numbers of target genes in each region are shown.
(F) Median fold changes (log2) of overlap of HTV and HTI (purple), only HTV (red), only HTI (blue), and total genes (black). Data are given as values compared to
uninfected.
(G) Venn diagram of HTV (ACE-score > 1, red) and HTD (ACE-score < 1, blue). The numbers of target genes in each region are shown.
(H) Median fold changes (log2) of overlap of HTV and HTD (purple), only HTV (red), only HTD (blue), and total genes (black). Data are given as values compared to
uninfected.
See also Figure S7 and Table S7.
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Luciferase Reporter Assay
HEK293T cells were seeded in 24-well plates 1 day before transfection. For co-
transfection, 5 ng firefly luciferase and 2.5 ng Renilla luciferase reporter plas-
mids were transiently transfected into cells with 20 pmol of miRNA artificial
oligomer (synthesized and annealed by Bioneer). After 24–48 hr, luciferase ac-
tivity wasmeasured with a Dual Luciferase Reporter Assay System (Promega).
Immunoblotting
Cells were lysed for 1 hr at 4C with 1% (v/v) Nonidet P-40 (NP-40) or RIPA
buffer in PBS with a protease-inhibitor cocktail, separated on a 4%–12% Nu-
PAGE Bis-Tris gel (NP0321BOX, Invitrogen) according to the manufacturer’s
instructions using 800 ml of 13 MOPS running buffer (NP0001, Invitrogen),
transferred onto nitrocellulose membranes with NuPAGE Transfer Buffer
(NP00061, Invitrogen), blocked with 3% BSA in Tris-buffered saline with
0.1% Tween 20 (0.1% TBST), and probed overnight with the appropriate an-
tibodies in 0.1% TBST. Membranes were washed with 0.1% TBST, incubated
for 1 hr with horseradish peroxidase-conjugated secondary antibody (Jackson
ImmunoResearch Laboratories), and finally washed with 0.1% TBST. Proteins
on immunoblots were visualized with ECLWestern Blotting Substrate (Thermo
Scientific Pierce).
Lactate Dehydrogenase Release Assay
HFFswere transfected with control or HCMVmiRNA oligomers for 48 hr before
treatment with or without 100 ng/ml recombinant human soluble FAS ligand
(sFASL; PeproTech, 310-03H) and harvested at 12 hr after sFASL treatment.
The LDH release assay was performed using an LDH Cytotoxicity Detection
Kit (Clontech, 630117) according to the manufacturer’s protocol.
Statistical Analysis
Statistical comparisons for cumulative relative frequency (fraction) were
conducted using the Kolmogorov-Smirnov test (K-S test) with XLSTAT
software. In the K-S test, p values % 0.0001 (*) were considered statistically
significant. Statistical comparisons for continuous variables were conducted
using bootstrapped t tests with 10,000 repetitions (Neuha¨user and Jo¨ckel,
2006). To compare discrete random variables, a Poisson generalized linear
model was applied to determine statistical significance. All data are shown
as means ± SEM. We conducted bootstrapped t test with in-house software
and used R statistical software (v. 3.0.1) for all other comparisons. p values%
0.05 (*), 0.01 (**), and 0.001 (***) were considered statistically significant.
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